Floatz logo

Anti-Cd30/Cd16A Monoclonal Antibody Afm13

Recurrent Anaplastic Large Cell Lymphoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the Recurrent Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Seagen Inc.
Phase 4BBB
Crizotinib
Pfizer
Phase 4BBB
Inno-206
City of Hope Medical Center
Phase 4BBB
Brentuximab Vedotin
Seagen Inc.
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti-Cd30/Cd16A Monoclonal Antibody Afm13 is also rated in:

mycosis fungoidesDormant
BB
Indicative ·
69 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
61 / 100
View asset →
Hodgkins lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →